On February 27, 2019, BRCA1 and BRCA2 Gene Mutation Detection Kit produced by AmoyDx（Amoy Diagnostics Co., Ltd.） (Weirujian) is approved by NMPA. As the second NGS product of AmoyDx approved by NMPA, it has become the first approved NGS detection product for BRCA mutation, filling the blank in this field.
The approval of multiple NGS products demonstrates that AmoyDx has brought the molecular detection of cancer cells, especially the NGS detection, to a new level. The successful approval of Weirujian marks a big step forward both to AmoyDx in NGS detection, and to the compliance detection of cancer and its pathology in female patients. It is our common wish to see that the wide-coverage and reliable Weirujian will play well its role in clinical detection, so as to help more patients receive targeted clinical treatment.
The approval of multiple NGS products demonstrates that AmoyDx has brought the molecular detection of cancer cells, especially the NGS detection, to a new level. The successful approval of Weirujian marks a big step forward both to AmoyDx in NGS detection, and to the compliance detection of cancer and its pathology in female patients. It is our common wish to see that the wide-coverage and reliable Weirujian will play well its role in clinical detection, so as to help more patients receive targeted clinical treatment.